Update on medications with adverse skeletal effects

Mayo Clinic Proceedings

Volumn 86, Issue 4, 2011, Pages 338-343

  Davidge Pitts, Caroline J ^a   Kearns, Ann E ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADENOSINE TRIPHOSPHATASE; ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; DENOSUMAB; ESTROGEN; EXEMESTANE; GLIBENCLAMIDE; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IBANDRONIC ACID; LETROZOLE; LOOP DIURETIC AGENT; MEDROXYPROGESTERONE ACETATE; METFORMIN; OMEPRAZOLE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PIOGLITAZONE; PLACEBO; PREDNISONE; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; TOREMIFENE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOLEDRONIC ACID;

APOPTOSIS; BONE DENSITY; BONE MASS; BONE MINERAL; BREAST CANCER; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CANCER GROWTH; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FRACTURE; FRAGILITY FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; HYPOGONADISM; LOW DRUG DOSE; MUSCLE WEAKNESS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRESCRIPTION; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 79953326548     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0636     Document Type: Review

References (45)

1. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319- 1328. (Pubitemid 47389469)
2. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res. 2005;20(3):464-470. (Pubitemid 40293495)
3. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60:3346-3355.
4. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-1526.
5. Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279-302. (Pubitemid 34651948)
6. Cummings SR, Browner WS, Bauer D, et al; Study of Osteoporotic Fractures Research Group. Endogenous hormones and the risk of hip and vertebral fractures among older women. N Engl J Med. 1998;339(11):733-738. (Pubitemid 28417356)
7. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 1998;83(7):2239-2243. (Pubitemid 28503008)
8. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ III, Riggs BL. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res. 2002;17:172-178. (Pubitemid 33151009)
9. Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: prevention with bisphosphonates. Bone. 2007;41(3):346-352.
10. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozoleinduced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14(19):6336-6342.
11. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829-836. (Pubitemid 350002883)
12. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840-849.
13. Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118(1):81-87.
14. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19(8):1407-1416.
15. Kaunitza AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception. Contraception. 2007;77(2):67-76.
16. Walsh JS, Eastell R, Peel NF. Effects of depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study. J Clin Endocrinol Metab. 2008;93(4):1317-1323. (Pubitemid 351519727)
17. Watson KC, Lentz MJ, Cain KC. Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities. Womens Health Issues. 2006;16(6):346-352. (Pubitemid 44937643)
18. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86(6):2787-2791. (Pubitemid 32545740)
19. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410-6417. (Pubitemid 41759293)
20. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154-164. (Pubitemid 40096612)
21. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23(31):7897-7903. (Pubitemid 46657388)
22. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25(9):1038-1042. (Pubitemid 46596753)
23. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345(13):948-955.
24. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Arch Intern Med. 2007;146(6):416-424. (Pubitemid 351650576)
25. Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179(1):152-155. (Pubitemid 350216737)
26. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(8):3841-3846. (Pubitemid 39071482)
27. Smith MR, Morton RA, Barnette KG, et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010;184(4):1316-1321.
28. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011;48(1):88-95.
29. Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010;152(10):621-629.
30. Jennermann C, Triantafillou J, Cowan D, Pennink B, Connolly K, Morris D. Effects of thiazolidinediones on bone turnover in the rat [Abstract]. J Bone Miner Res.1995;10(suppl 1):S241.
31. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356(13):1387-1388]. N Engl J Med. 2006;355(23):2427-2443.
32. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS. An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest. 1984;73(3):640-647. (Pubitemid 14156843)
33. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. Nephrol Dial Transplant. 1995;10(8):1376-1380.
34. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76-83. (Pubitemid 44306164)
35. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-326.
36. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-2953. (Pubitemid 46021498)
37. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int. 2009;84(1):13-19.
38. Yu EW, Blackwell T, Ensrud KE, et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251-259.
39. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology. 2005;146(2):685-693. (Pubitemid 40129824)
40. Richards JB, Papaioannou A, Adachi JD, et al; Canadian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reupdate inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188-194.
41. Ziere G, Dieleman JP, van der Cammen TJ, Hofman A, Pols HA, Stricker BH. Selective serotonin reuptake inhibiting antidepressants are associated with increased risk of nonvertebral fractures. J Clin Psychopharmacol. 2008;28(4):411-417.
42. Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women. Arch Intern Med. 2007;167(12):1240-1245.
43. Haney EM, Chan BK, Diem SJ, et al; Osteoporotic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007;167(12):1246-1251.
44. Williams LJ, Henry MJ, Berk M, et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with history of depression. Int Clin Psychopharmacol. 2008;23(2):84-87. (Pubitemid 351317280)
45. Verdel BM, Souverein PC, Egberts TC, van Staa TP, Leufkens HG, de Vries F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone. 2010;47(3):604-609.